{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:19:23Z","timestamp":1781659163449,"version":"3.54.5"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.cytogfr.2021.03.001","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T07:29:05Z","timestamp":1615102145000},"page":"46-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The conundrum of current anti-SARS-CoV-2 vaccines"],"prefix":"10.1016","volume":"60","author":[{"given":"Maurizio","family":"Federico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytogfr.2021.03.001_bib0005","unstructured":"COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) https:\/\/coronavirus.jhu.edu\/map.html."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0010","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/589862","article-title":"Vaccines: correlates of vaccine-induced immunity","volume":"47","author":"Plotkin","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0015","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","author":"Dan","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0025","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","author":"McMahan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0030","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S1473-3099(20)30364-9","article-title":"SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series","volume":"20","author":"Hung","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0035","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","article-title":"Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections","volume":"26","author":"Long","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0040","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.immuni.2020.10.004","article-title":"Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity","volume":"53","author":"Ripperger","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0045","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1172\/JCI138759","article-title":"Kinetics of viral load and antibody response in relation to COVID-19 severity","volume":"130","author":"Wang","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0050","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/s41590-020-00814-z","article-title":"Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19","volume":"21","author":"Woodruff","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0055","doi-asserted-by":"crossref","first-page":"108728","DOI":"10.1016\/j.celrep.2021.108728","article-title":"Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients","author":"Tan","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0060","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0065","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent antibody responses to SARS-CoV-2 in convalescent individuals","volume":"584","author":"Robbiani","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0070","article-title":"Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset","author":"Anand","year":"2021","journal-title":"BioRxiv"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0075","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abe0240","article-title":"Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome","volume":"5","author":"R\u00f6ltgen","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0080","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity","volume":"183","author":"Rydyznski Moderbacher","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0085","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.immuni.2020.07.020","article-title":"Distinct early serological signatures track with SARS-CoV-2 survival","volume":"53","author":"Atyeo","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0090","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","author":"Long","year":"2020","journal-title":"Nat. Med."},{"issue":"21","key":"10.1016\/j.cytogfr.2021.03.001_bib0095","article-title":"Deciphering the protective features of the antibody response","volume":"70","author":"Flemming","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0100","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1056\/NEJMoa2026116","article-title":"Humoral immune response to SARS-CoV-2 in Iceland","volume":"383","author":"Gudbjartsson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0105","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1080\/22221751.2020.1762515","article-title":"Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients","volume":"9","author":"Sun","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0110","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2020.11.029","article-title":"Functional SARS-CoV-2-Specific immune memory persists after mild COVID-19","volume":"184","author":"Rodda","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0115","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-021-03207-w","article-title":"Evolution of antibody immunity to SARS-CoV-2","author":"Gaebler","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0120","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.immuni.2021.01.014","article-title":"B cell memory: understanding COVID-19","volume":"54","author":"Quast","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0125","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev.immunol.021908.132625","article-title":"Immunity to respiratory viruses","volume":"27","author":"Kohlmeier","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0130","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0135","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0140","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/mt.2013.124","article-title":"Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics","volume":"21","author":"Maier","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0145","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0150","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-Based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0155","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"mRNA-1273 Study Group, An mRNA Vaccine against SARS-CoV-2 - Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0160","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"mRNA-1273 study group, safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0165","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)00448-7","article-title":"Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients","author":"Amit","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0170","article-title":"Patterns of COVID-19 pandemic dynamics following deployment of a broad national immunization program","author":"Rossman","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0175","article-title":"FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system","author":"Pawlowski","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0180","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1002\/1873-3468.13700","article-title":"Lessons learned from adenovirus (1970\u20132019)","volume":"593","author":"Nemerow","year":"2019","journal-title":"FEBS Lett."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0185","series-title":"Adenoviral Vectors, Materials and Methods","author":"Khatun","year":"2020"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0190","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21103643","article-title":"High-capacity adenoviral vectors: expanding the scope of gene therapy","volume":"21","author":"Ricobaraza","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0195","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/jmv.23546","article-title":"Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults","volume":"85","author":"Zhang","year":"2013","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2010.07.043","article-title":"Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys","volume":"407","author":"Ersching","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0205","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"Abbink","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0210","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0215","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0220","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0225","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.vaccine.2009.10.091","article-title":"Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive","volume":"28","author":"Hutnick","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0230","article-title":"Oxford COVID Vaccine Trial Group, T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial","author":"Ewer","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0235","article-title":"Oxford COVID Vaccine Trial Group, Phase 1\/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses","author":"Barrett","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0240","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0245","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Oxford COVID Vaccine Trial Group, Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0250","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12985-020-01387-x","article-title":"Whole genomic analysis of a potential recombinant human adenovirus type 1 in Qinghai plateau, China","volume":"17","author":"Yu","year":"2020","journal-title":"Virol. J."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0255","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1038\/s41598-018-37756-4","article-title":"Genome analysis of a novel recombinant human adenovirus type 1 in China","volume":"9","author":"Zhang","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0260","doi-asserted-by":"crossref","first-page":"23014","DOI":"10.1038\/srep23014","article-title":"Phylogenetic evidence for intratypic recombinant events in a novel human adenovirus C that causes severe acute respiratory infection in children","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0265","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0270","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0275","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nri1732","article-title":"Immunopathogenesis of coronavirus infections: implications for SARS","volume":"5","author":"Perlman","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0280","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1743-422X-11-82","article-title":"Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus","volume":"11","author":"Yip","year":"2014","journal-title":"Virol. J."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0285","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123158","article-title":"Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection","volume":"4","author":"Liu","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0290","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41586-020-2538-8","article-title":"A perspective on potential antibody-dependent enhancement of SARS-CoV-2","volume":"584","author":"Arvin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0295","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","article-title":"Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies","volume":"5","author":"Lee","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0300","article-title":"At the intersection between SARS-CoV-2, macrophages and the adaptive immune response: a key role for antibody-dependent pathogenesis but not enhancement of infection in COVID-19","author":"DeMarco","year":"2021","journal-title":"BioRxiv"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0305","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0310","first-page":"417","article-title":"Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo","volume":"58","author":"Taylor","year":"1986","journal-title":"Immunology"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0315","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1172\/JCI115362","article-title":"Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice","volume":"88","author":"Graham","year":"1991","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0320","doi-asserted-by":"crossref","first-page":"9318","DOI":"10.1128\/JVI.01049-10","article-title":"T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice","volume":"84","author":"Zhao","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0325","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of t cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0330","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2598-9","article-title":"SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19","volume":"587","author":"Braun","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0335","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.immuni.2020.04.023","article-title":"Detection of SARS-CoV-2-Specific humoral and cellular immunity in COVID-19 convalescent individuals","volume":"52","author":"Ni","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0340","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd2071","article-title":"Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome","volume":"5","author":"Weiskopf","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0345","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust t cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0350","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"Le Bert","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0355","article-title":"Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","author":"Garcia-Beltran","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.cytogfr.2021.03.001_bib0360","unstructured":"D. Planas, T. Bruel, L. Grzelak, F. Guivel-Benhassine, I. Staropoli, F. Porrot, C. Planchais, J. Buchrieser, M. M. Rajah, E. Bishop, M. Albert, F. Donati, S. Behillil, V. Enouf, M. Maquart, M. Gonzalez, J. De S\u00e8ze, H. P\u00e9r\u00e9, D. Veyer, A. S\u00e8ve, E. Simon Lori\u00e8re, S. Fafi-Kremer, K. Stefic, H. Mouquet, L. Hocqueloux, S. van der Werf, T. Prazuck, O. Schwartz, Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies bioRxiv, (n.d.). https:\/\/www.biorxiv.org\/content\/10.1101\/2021.02.12.430472v1."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610121000265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610121000265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:01:37Z","timestamp":1761217297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610121000265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":72,"alternative-id":["S1359610121000265"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2021.03.001","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The conundrum of current anti-SARS-CoV-2 vaccines","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2021.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}